echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Lancet sub-issue my country Air Force Military Medical University: Don't underestimate enteral nutrition, it can affect the prognosis of stroke!

    Lancet sub-issue my country Air Force Military Medical University: Don't underestimate enteral nutrition, it can affect the prognosis of stroke!

    • Last Update: 2022-04-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Early enteral nutrition is critical for preventing malnutrition and improving outcomes in severe stroke patients , but previous trials have provided conflicting results on optimal nutritional strategies
    .
    In order to compare the efficacy and safety of three enteral feeding strategies for severe stroke patients, experts from Xijing Hospital Affiliated to Air Force Military Medical University conducted a related study and the results were published in the journal Lancet Neurology


    .


    Early enteral nutrition is critical for preventing malnutrition and improving prognosis in severe stroke patients Early enteral nutrition is critical for preventing malnutrition and improving prognosis in severe stroke patients

    The Optimal Early Enteral Nutrition in Severe Stroke Study (OPENS) is a multicenter, investigator-initiated, prospective, open-label, randomized controlled trial with blinded evaluations in 16 tertiary grade-A hospitals and district-level general hospitals in western China
    .

    Adult patients with acute major ischemic or hemorrhagic stroke (GCS ≤12 or NIHSS ≥11 on admission), expected to receive enteral nutrition for more than 7 days, were randomly assigned (1:1:1) by centralized Network randomized systematic assignment to total enteral nutrition (70-100% of estimated caloric needs), modified total enteral nutrition (full enteral nutrition plus agonists), or low-calorie enteral nutrition (40-100% of estimated caloric needs) 60%)
    .

    The indicated nutrition started within 24 hours of enrollment and continued for 7 days
    .
    The primary efficacy outcome was the proportion of participants with a poor outcome (modified Rankin Scale score ≥ 3) at day 90, and the prespecified primary safety outcome was mortality at day 90


    .


    During 2017-2020, 321 patients were randomly assigned (107 in each group), and 315 patients (175 [56%] men, median age 71 years, IQR 60-78) were included in the final analysis
    .
    The study was terminated early on September 23, 2020, because a significant between-group difference was found in mortality


    .


    The study was terminated early on September 23, 2020, because a significant between-group difference was found in mortality


    After 90 days, there was no difference in the proportion of participants with an adverse outcome (modified full enteral nutrition 86/105 [82%] vs full enteral nutrition 85/106 [80%], OR = 0.


    Further analysis showed that the 90-day mortality rate of low-calorie enteral nutrition was significantly higher than that of modified full enteral nutrition, with a nearly 2-fold increased risk (35/104 [34%] vs 18/105 [17%], OR=2.


    89 , 95%CI 1.


    Further analysis showed that the 90-day mortality rate of low-calorie enteral nutrition was significantly higher than that of modified full enteral nutrition, with a nearly 2-fold increased risk (35/104 [34%] vs 18/105 [17%], OR=2.


    CONCLUSIONS: In the early stages of severe stroke, modified full or low-calorie enteral nutrition did not significantly reduce the risk of adverse outcomes compared with full enteral nutrition over 90 days


    references:

    Safety and efficacy of three enteral feeding strategies in patients with severe stroke in China (OPENS): a multicentre, prospective, randomised, open-label, blinded-endpoint trial.


    https://doi.


    Safety and efficacy of three enteral feeding strategies in patients with severe stroke in China (OPENS): a multicentre, prospective, randomised, open-label, blinded-endpoint trial.
    Leave a comment here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.